Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10475977rdf:typepubmed:Citationlld:pubmed
pubmed-article:10475977lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:10475977lifeskim:mentionsumls-concept:C0358297lld:lifeskim
pubmed-article:10475977lifeskim:mentionsumls-concept:C0301872lld:lifeskim
pubmed-article:10475977pubmed:issue2lld:pubmed
pubmed-article:10475977pubmed:dateCreated1999-11-4lld:pubmed
pubmed-article:10475977pubmed:abstractTextThe IgG anti-protective antigen subclass antibody response of individuals who had been infected with anthrax was compared with that of healthy individuals immunized with the UK licensed anthrax vaccine. The predominant subclass in both groups was IgG1. In addition, IgG3 was seen in convalescent serum while vaccinees produced IgG2, IgG3 and IgG4 subclass. The significance of these results is discussed. Further work is required to determine the role of antibodies in mediating protective immunity in man.lld:pubmed
pubmed-article:10475977pubmed:languageenglld:pubmed
pubmed-article:10475977pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10475977pubmed:citationSubsetIMlld:pubmed
pubmed-article:10475977pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10475977pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10475977pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10475977pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10475977pubmed:statusMEDLINElld:pubmed
pubmed-article:10475977pubmed:monthAuglld:pubmed
pubmed-article:10475977pubmed:issn1364-5072lld:pubmed
pubmed-article:10475977pubmed:authorpubmed-author:TurnbullP CPClld:pubmed
pubmed-article:10475977pubmed:authorpubmed-author:BaillieL WLWlld:pubmed
pubmed-article:10475977pubmed:authorpubmed-author:FowlerKKlld:pubmed
pubmed-article:10475977pubmed:issnTypePrintlld:pubmed
pubmed-article:10475977pubmed:volume87lld:pubmed
pubmed-article:10475977pubmed:ownerNLMlld:pubmed
pubmed-article:10475977pubmed:authorsCompleteYlld:pubmed
pubmed-article:10475977pubmed:pagination306-8lld:pubmed
pubmed-article:10475977pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:10475977pubmed:meshHeadingpubmed-meshheading:10475977...lld:pubmed
pubmed-article:10475977pubmed:meshHeadingpubmed-meshheading:10475977...lld:pubmed
pubmed-article:10475977pubmed:meshHeadingpubmed-meshheading:10475977...lld:pubmed
pubmed-article:10475977pubmed:meshHeadingpubmed-meshheading:10475977...lld:pubmed
pubmed-article:10475977pubmed:meshHeadingpubmed-meshheading:10475977...lld:pubmed
pubmed-article:10475977pubmed:meshHeadingpubmed-meshheading:10475977...lld:pubmed
pubmed-article:10475977pubmed:meshHeadingpubmed-meshheading:10475977...lld:pubmed
pubmed-article:10475977pubmed:meshHeadingpubmed-meshheading:10475977...lld:pubmed
pubmed-article:10475977pubmed:meshHeadingpubmed-meshheading:10475977...lld:pubmed
pubmed-article:10475977pubmed:meshHeadingpubmed-meshheading:10475977...lld:pubmed
pubmed-article:10475977pubmed:year1999lld:pubmed
pubmed-article:10475977pubmed:articleTitleHuman immune responses to the UK human anthrax vaccine.lld:pubmed
pubmed-article:10475977pubmed:affiliationDERA Chemical and Biological Defence Sector, Porton Down, Salisbury, Wilts, UK.lld:pubmed
pubmed-article:10475977pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10475977pubmed:publicationTypeComparative Studylld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10475977lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10475977lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10475977lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10475977lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10475977lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10475977lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10475977lld:pubmed